Title : Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies - Neumiller_2008_Diabetes.Educ_34_183 |
Author(s) : Neumiller JJ , Odegard PS , White JR, Jr. , Setter SM , Campbell RK |
Ref : Diabetes Educ , 34 :183 , 2008 |
Abstract :
Strong evidence exists demonstrating the benefits of tight glycemic control in type 1 and type 2 diabetes mellitus patients, but glycemic goals are not adequately achieved for many patients. Advancement in the knowledge surrounding the physiology of endogenous glucoregulatory peptide hormones, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, has led to new therapeutic targets for the treatment of type 2 diabetes mellitus. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide practitioners with a novel mechanism of action to use for combination therapies for the treatment of type 2 diabetes mellitus. This article, part 3 of a 3-part series, reviews the new class of medications known as DPP-4 inhibitors as well as discusses a future buccal insulin formulation, Oral-Lyn, on the horizon for the treatment of diabetes mellitus. |
PubMedSearch : Neumiller_2008_Diabetes.Educ_34_183 |
PubMedID: 18375772 |
Neumiller JJ, Odegard PS, White JR, Jr., Setter SM, Campbell RK (2008)
Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies
Diabetes Educ
34 :183
Neumiller JJ, Odegard PS, White JR, Jr., Setter SM, Campbell RK (2008)
Diabetes Educ
34 :183